Contemporary Concise Review 2023: Asthma.

Publisher: Blackwell Science Country of Publication: Australia NLM ID: 9616368 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1440-1843 (Electronic) Linking ISSN: 13237799 NLM ISO Abbreviation: Respirology Subsets: MEDLINE

Original Publication: Carlton, Vic. : Blackwell Science, c1996-

Asthma*/drug therapy ; Adrenal Cortex Hormones*/therapeutic use ; Adrenal Cortex Hormones*/administration & dosage; Humans ; Anti-Asthmatic Agents/therapeutic use ; Precision Medicine/methods ; Disease Progression

Asthma research and management needs to meet the priorities of the end user-patients, carers and clinicians. A better understanding of the natural history of asthma and the progression of disease has highlighted the importance of early identification of patients with asthma and the potential role of early intervention. Management of mild asthma requires a consistent approach with the same detail and consideration used when managing severe disease. Evidence around treatable traits approaches continues to evolve, supporting the role of a personalized medicine in asthma. Oral corticosteroid (OCS) stewardship continues to be an urgent issue in asthma management. Strategies to taper OCS doses and the implementation of biologic therapies for their steroid sparing benefits will be important steps to address this problem. The concept of remission in asthma provides an ambitious target and treatment outcome.
(© 2024 The Author(s). Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.)

Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gülmezoglu AM, et al. How to increase value and reduce waste when research priorities are set. Lancet. 2014 Jan;383(9912):156–165.
Majellano EC, Bell RL, Flynn AW, Mckenzie A, Sivamalai S, Goldman M, et al. Identifying the asthma research priorities of people with asthma, their carers and other stakeholders. Respirology. 2023 Jul;28(7):636–648.
Collins‐Fairclough A, Rideout K, Joshi P, Philips J, Lanier T, Chow S, et al. Opportunities to improve asthma and COPD prevention and care: insights from the patient journey obtained through focus groups. BMJ Open Qual. 2023 Dec;12(4):e002403.
Zhang X, Buttery SC, Sterniczuk K, Brownrigg A, Kennington E, Quint JK. Patient experiences of communication with healthcare professionals on their healthcare management around chronic respiratory diseases. Healthcare. 2023 Jul 31;11(15):2171.
Agusti A, Faner R. Lung function trajectories in health and disease. Lancet Respir Med. 2019 Apr;7(4):358–364.
Agustí A, Noell G, Brugada J, Faner R. Lung function in early adulthood and health in later life: a transgenerational cohort analysis. Lancet Respir Med. 2017 Dec;5(12):935–945.
Melén E, Faner R, Allinson JP, Bui D, Bush A, Custovic A, et al. Lung‐function trajectories: relevance and implementation in clinical practice. Lancet. 2024 Apr;403(10435):1494–1503.
Zhang X, Gray AR, Hancox RJ. Distinct trajectories of lung function from childhood to mid‐adulthood. Thorax. 2024 Mar 18;thorax‐2023‐220436. https://doi.org/10.1136/thorax-2023-220436.
Soremekun S, Heaney LG, Skinner D, Bulathsinhala L, Carter V, Chaudhry I, et al. Asthma exacerbations are associated with a decline in lung function: a longitudinal population‐based study. Thorax. 2023 Jul;78(7):643–652.
Von Bülow A, Hansen S, Sandin P, Ernstsson O, Janson C, Lehtimäki L, et al. Severe asthma trajectories in adults: findings from the NORDSTAR cohort. Eur Respir J. 2023 Sep;62(3):2202474.
Mohan A, Lugogo NL, Hanania NA, Reddel HK, Akuthota P, O'Byrne PM, et al. Questions in mild asthma: an official American Thoracic Society Research Statement. Am J Respir Crit Care Med. 2023 Jun 1;207(11):e77–e96.
Jenkins CR. Mild asthma: conundrums, complexities and the need to customize care. Respirology. 2024 Feb;29(2):94–104.
De Las VL, Quirce S. Landscape of short‐acting beta‐agonists (SABA) overuse in Europe. Clin Exp Allergy. 2023 Feb;53(2):132–144.
Bateman ED, Price DB, Wang HC, Khattab A, Schonffeldt P, Catanzariti A, et al. Short‐acting β 2 ‐agonist prescriptions are associated with poor clinical outcomes of asthma: the multi‐country, cross‐sectional SABINA III study. Eur Respir J. 2022 May;59(5):2101402.
Lugogo N, O'Connor M, George M, Merchant R, Bensch G, Portnoy J, et al. Expert consensus on SABA use for asthma clinical decision‐making: a Delphi approach. Curr Allergy Asthma Rep. 2023 Nov;23(11):621–634.
Sriprasart T, Waterer G, Garcia G, Rubin A, Andrade MAL, Roguska A, et al. Safety of SABA monotherapy in asthma management: a systematic review and meta‐analysis. Adv Ther. 2023 Jan;40(1):133–158.
Bigoni T, Alfano F, Baraldi F, Contoli M, Papi A. Evaluating as‐needed inhaled corticosteroid strategies in asthma: expanding the benefits to mild asthma. Expert Rev Respir Med. 2023 Aug 3;17(8):623–634.
Papi A, Ferreira DS, Agache I, Baraldi E, Beasley R, Brusselle G, et al. European Respiratory Society short guidelines for the use of as‐needed ICS/formoterol in mild asthma. Eur Respir J. 2023 Oct;62(4):2300047.
Chung LP, Johnson P, Summers Q. Models of care for severe asthma: the role of primary care. Med J Aust. 2018 Jul 16;209(S2):S34–S40.
Levy ML, Bacharier LB, Bateman E, Boulet LP, Brightling C, Buhl R, et al. Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update. npj Prim Care Respir Med. 2023 Feb 8;33(1):7.
Lommatzsch M, Brusselle GG, Levy ML, Canonica GW, Pavord ID, Schatz M, et al. A2BCD: a concise guide for asthma management. Lancet Respir Med. 2023 Jun;11(6):573–576.
Reddel HK, Sawyer SM, Everett PW, Flood PV, Peters MJ. Asthma control in Australia: a cross‐sectional web‐based survey in a nationally representative population. Med J Aust. 2015 May;202(9):492–496.
Nash JL, Southcott AM, Jayaram L. Quality of acute asthma care: an audit of clinical practice in a Victorian health service. Intern Med J. 2023 Jun;53(6):985–993.
Berger DJ, King S, Caldwell C, Soto E, Chambers A, Boehmer S, et al. Returns after discharge from the emergency department observation unit: who, what, when, and why? West J Emerg Med. 2023 May 3;24(3):390–395.
Mayers I, Randhawa A, Qian C, Talukdar M, Soliman M, Jayasingh P, et al. Asthma‐related emergency admissions and associated healthcare resource use in Alberta, Canada. BMJ Open Respir Res. 2023 Oct;10(1):e001934.
Shah PA, Brightling C. Biologics for severe asthma—which, when and why? Respirology. 2023 Aug;28(8):709–721.
Rogers L, Jesenak M, Bjermer L, Hanania NA, Seys SF, Diamant Z. Biologics in severe asthma: a pragmatic approach for choosing the right treatment for the right patient. Respir Med. 2023 Nov;218:107414.
Nopsopon T, Lassiter G, Chen ML, Alexander GC, Keet C, Hong H, et al. Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta‐analysis. J Allergy Clin Immunol. 2023 Mar;151(3):747–755.
Langton D, Politis J, Collyer T, Khung S, Bardin P. Benralizumab and mepolizumab treatment outcomes in two severe asthma clinics. Respirology. 2023 Aug;28:1117–1125.
Kurihara M, Kabata H, Irie M, Fukunaga K. Current summary of clinical studies on anti‐TSLP antibody, Tezepelumab, in asthma. Allergol Int. 2023 Jan;72(1):24–30.
Corren J, Menzies‐Gow A, Chupp G, Israel E, Korn S, Cook B, et al. Efficacy of Tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023 Jul 1;208(1):13–24.
Rogliani P, Laitano R, Ora J, Beasley R, Calzetta L. Strength of association between comorbidities and asthma: a meta‐analysis. Eur Respir Rev. 2023 Mar;32(167):220202.
Sarwar MR, McDonald VM, Abramson MJ, McLoughlin RF, Geethadevi GM, George J. Effectiveness of interventions targeting treatable traits for the Management of Obstructive Airway Diseases: a systematic review and meta‐analysis. J Allergy Clin Immunol Pract. 2022 Sep;10(9):2333–2345.e21.
Gibson PG, McDonald VM, Thomas D. Treatable traits, combination inhaler therapy and the future of asthma management. Respirology. 2023;28(9):828–840.
Pavord ID, Deniz Y, Corren J, Casale TB, FitzGerald JM, Izuhara K, et al. Baseline FeNO independently predicts the Dupilumab response in patients with moderate‐to‐severe asthma. J Allergy Clin Immunol Pract. 2023 Apr 1;11(4):1213–1220.e2.
Pfeffer PE, Ali N, Murray R, Ulrik C, Tran TN, Maspero J, et al. Comparative effectiveness of anti‐IL5 and anti‐IgE biologic classes in patients with severe asthma eligible for both. Allergy. 2023 Jul;78(7):1934–1948.
Beasley R, Hughes R, Agusti A, Calverley P, Chipps B, Del Olmo R, et al. Prevalence, diagnostic utility and associated characteristics of bronchodilator responsiveness. Am J Respir Crit Care Med. 2024 Feb 15;209(4):390–401.
Leong P, Gibson PG, Vertigan AE, Hew M, McDonald VM, Bardin PG. Vocal cord dysfunction/inducible laryngeal obstruction—2022 Melbourne roundtable report. Respirology. 2023;28(7):615–626.
Leong P, Vertigan AE, Hew M, Baxter M, Phyland D, Hull JH, et al. Diagnosis of vocal cord dysfunction / inducible laryngeal obstruction—a Delphi study protocol. PLoS One. 2022 Dec 29;17(12):e0279338.
Burns CM. The history of cortisone discovery and development. Rheum Dis Clin North Am. 2016 Feb;42(1):1–14.
Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ. 1996 Aug 10;313(7053):344–346.
Hew M, McDonald VM, Bardin PG, Chung LP, Farah CS, Barnard A, et al. Cumulative dispensing of high oral corticosteroid doses for treating asthma in Australia. Med J Aust. 2020 Oct;213(7):316–320.
Bleecker ER, Menzies‐Gow AN, Price DB, Bourdin A, Sweet S, Martin AL, et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med. 2020 Feb 1;201(3):276–293.
Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling Zhi Jie J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long‐term observational study. J Asthma Allergy. 2018 Aug;11:193–204.
Dhar R, Rhee CK, Perng D, Fukunaga K, Ip MS, Juthong S, et al. The burden of systemic corticosteroid use in asthma management in Asia. Respirology. 2023 Aug;28(8):744–757.
Ko FWS, Salvi S. Minimize systemic oral corticosteroids use and reduce harm for patients with asthma. Respirology. 2023 Aug;28(8):694–695.
Blakey J, Chung LP, McDonald VM, Ruane L, Gornall J, Barton C, et al. Oral corticosteroids stewardship for asthma in adults and adolescents: a position paper from the Thoracic Society of Australia and New Zealand. Respirology. 2021 Dec;26(12):1112–1130.
Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid‐sparing effect of Mepolizumab in eosinophilic asthma. N Engl J Med. 2014 Sep 25;371(13):1189–1197.
Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral glucocorticoid–sparing effect of Benralizumab in severe asthma. N Engl J Med. 2017 Jun 22;376(25):2448–2458.
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate‐to‐severe uncontrolled asthma. N Engl J Med. 2018 Jun 28;378(26):2486–2496.
Politis J, Chung LP, Igwe E, Bardin P, Gibson PG. Oral corticosteroid stewardship: key insights from the Australasian Severe Asthma Registry. Intern Med J. 2024. https://doi.org/10.1111/imj.16392.
Pilette C, Canonica GW, Chaudhuri R, Chupp G, Lee FEH, Lee JK, et al. REALITI‐A study: real‐world Oral corticosteroid‐sparing effect of Mepolizumab in severe asthma. J Allergy Clin Immunol Pract. 2022 Oct;10(10):2646–2656.
Menzies‐Gow A, Gurnell M, Heaney LG, Corren J, Bel EH, Maspero J, et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open‐label, single‐arm study. Lancet Respir Med. 2022 Jan;10(1):47–58.
Suehs CM, Menzies‐Gow A, Price D, Bleecker ER, Canonica GW, Gurnell M, et al. Expert consensus on the tapering of oral corticosteroids for the treatment of asthma. A Delphi study. Am J Respir Crit Care Med. 2021 Apr 1;203(7):871–881.
Hancox RJ, Bardin PG. Asthma research priorities: listening to everybody. Respirology. 2023 Jul;28(7):592–593.
Vu HD, Shafuddin E, Willis J, Pallin M, Armstrong D, Daley C. Monoclonal antibody therapy in cystic fibrosis and asthma. Respirology. 2023 Jun;28(6):571–574.
Al‐Shaikhly T, Murphy RC, Lai Y, Frevert CW, Debley JS, Ziegler SF, et al. Sputum periostin is a biomarker of type 2 inflammation but not airway dysfunction in asthma. Respirology. 2023 May;28(5):491–494.
Menzies‐Gow A, Bafadhel M, Busse WW, Casale TB, Kocks JWH, Pavord ID, et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020 Mar;145(3):757–765.
Martin AJ, McLennan LA, Landau LI, Phelan PD. The natural history of childhood asthma to adult life. BMJ. 1980 Jun 14;280(6229):1397–1400.
Canonica GW, Blasi F, Carpagnano GE, Guida G, Heffler E, Paggiaro P, et al. Severe asthma network Italy definition of clinical remission in severe asthma: a Delphi consensus. J Allergy Clin Immunol Pract. 2023 Dec;11(12):3629–3637.
Lommatzsch M. Remission in asthma. Curr Opin Pulm Med. 2024 May;30(3):325–329.
Guo YL, Ampon MR, Poulos LM, Davis SR, Toelle BG, Marks GB, et al. Contribution of obesity to breathlessness in a large nationally representative sample of Australian adults. Respirology. 2023 Apr;28(4):350–356.
Yasaratne D, Idrose NS, Dharmage SC. Asthma in developing countries in the Asia‐Pacific Region (APR). Respirology. 2023 Nov;28(11):992–1004.
Jackson DJ, Heaney LG, Humbert M, Kent BD, Shavit A, Hiljemark L, et al. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open‐label, phase 4 study. Lancet. 2024 Jan;403(10423):271–281.
Thomas D, McDonald VM, Pavord ID, Gibson PG. Asthma remission: what is it and how can it be achieved? Eur Respir J. 2022 Nov;60(5):2102583.
Lavoie G, Pavord ID. Which biologic? New findings from a real‐world study. Respirology. 2023 Dec;28(12):1091–1092.
Shamji MH, Ollert M, Adcock IM, Bennett O, Favaro A, Sarama R, et al. EAACI guidelines on environmental science in allergic diseases and asthma – leveraging artificial intelligence and machine learning to develop a causality model in exposomics. Allergy. 2023;78(7):1742–1757.
Kang N, Lee K, Byun S, Lee JY, Choi DC, Lee BJ. Novel artificial intelligence‐based technology to diagnose asthma using methacholine challenge tests. Allergy Asthma Immunol Res. 2023 Dec 15;16(1):42–54.
Topole E, Biondaro S, Montagna I, Corre S, Corradi M, Stanojevic S, et al. Artificial intelligence based software facilitates spirometry quality control in asthma and COPD clinical trials. ERJ Open Res [Internet]. 2023 Jan 1 [cited 2024 Apr 13]. Available from: https://openres.ersjournals.com/content/9/1/00292-2022;9(1):00292‐2022.
Hogan AH, Brimacombe M, Mosha M, Flores G. Comparing artificial intelligence and traditional methods to identify factors associated with pediatric asthma readmission. Acad Pediatr. 2022 Jan 1;22(1):55–61.
Sagheb E, Wi CI, Yoon J, Seol HY, Shrestha P, Ryu E, et al. Artificial intelligence assesses Clinicians' adherence to asthma guidelines using electronic health records. J Allergy Clin Immunol Pract. 2022 Apr 1;10(4):1047–1056.e1.

Keywords: asthma; asthma control; oral corticosteroid stewardship; remission; treatable traits

0 (Adrenal Cortex Hormones)
0 (Anti-Asthmatic Agents)

Date Created: 20240628 Date Completed: 20240717 Latest Revision: 20240717

20240718

10.1111/resp.14782

38940241